A real-world analysis of survival and cost-effectiveness of sintilimab plus bevacizumab biosimilar regimen in patients with advanced hepatocellular carcinoma
Xianghua Zeng, Ying-xin Jia, Hongmei Chen, Qinli Luo, Huakan Zhao, Guanzhong Liang, Wen Chen, Yongsheng Li
Topics & Concepts
MedicineBevacizumabInternal medicineHepatocellular carcinomaAdverse effectRegimenOncologyCohortProgression-free survivalSurgeryOverall survivalChemotherapyCancer Immunotherapy and BiomarkersBiosimilars and Bioanalytical MethodsHepatocellular Carcinoma Treatment and Prognosis